Sedana Medical AB

Equities

SEDANA

SE0015988373

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm Other stock markets 08:59:53 03/06/2024 pm IST			5-day change	1st Jan Change
25.8 ^SEK	-4.44%		+20.00%	+11.40%

29/05	Sedana Medical AB Completes Patient Recruitment for its Clinical Program in the US	CI
22/05	Sedana Medical AB Approves Election of Jens Viebke and Donna Haire as Board Members	CI

Sedana Medical AB Announces Resignation of Its CEO Christer Ahlberg

February 25, 2021 at 01:30 am IST

Sedana Medical AB (publ) announced that Christer Ahlberg has informed the board of directors of Sedana Medical that he is resigning as CEO to become CEO of Cinclus Pharma AB. Christer Ahlberg will remain as CEO until the summer of 2021 and the board is starting a process to find a replacement.

Latest news about Sedana Medical AB

Sedana Medical AB Completes Patient Recruitment for its Clinical Program in the US	29/05	CI
Sedana Medical AB Approves Election of Jens Viebke and Donna Haire as Board Members	22/05	CI
Transcript : Sedana Medical AB, Q1 2024 Earnings Call, Apr 25, 2024	25/04
Sedana Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US	25/04	CI
Ola Magnusson and Eva Walde Decline Re-Election as Board Members of Sedana Medical AB	22/04	CI
Transcript : Sedana Medical AB, Q4 2023 Earnings Call, Feb 15, 2024	15/02
Sedana Medical AB Reports Earnings Results for the Full Year Ended December 31, 2023	15/02	CI
Sedana Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02	CI
Sedana Medical Seeks Pediatric Indication for Sedaconda Medical Device	20/12	MT
Sedana Medical AB Files Submission for Paediatric Indication	20/12	CI
Sedana Medical’s Sedaconda Gains Data Exclusivity, Market Protection in Europe	22/11	MT
Sedana Medical Secures Data Exclusivity and Market Protection for Sedaconda Until 2031	22/11	CI
Sedana Medical AB Announces the Main Results from the Paediatric Isocomfort Study	16/11	CI
Transcript : Sedana Medical AB, Nine Months 2023 Earnings Call, Oct 26, 2023	26/23/26
Sedana Medical AB Provides Earnings Guidance for the Year 2023	26/23/26	CI
Sedana Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/23/26	CI
Sedana Medical AB Establishes Nomination Committee	24/23/24	CI
Sedana Medical Completes Patient Enrollment for Sevoflurane Trial	23/23/23	MT
Sedana Medical AB Announces Completion of Enrollment	23/23/23	CI
Sedana Medical Wins UK Marketing Approval for Isoflurane Drug; Shares Jump 10%	10/23/10	MT
Sedana Medical AB Announces Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for Sedaconda in United Kingdom	10/23/10	CI
Sedana Medical Secures US Patent for Anesthetic Administration Medical Device	29/23/29	MT
Transcript : Sedana Medical AB, Q2 2023 Earnings Call, Jul 21, 2023	21/23/21
Sedana Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/23/21	CI

Chart Sedana Medical AB

Duration

Period

More charts

Company Profile

Sedana Medical AB (publ) is a Sweden-based medical technology company. It develops, markets and sales medical devices and conducts drug development for future projects around AnaConDa technology. The AnaConDa technology delivery enables of volatile anaesthetics to invasively ventilated patients. The products portfolio comprises disposable medical devices AnaConDa for administration of volatile anaesthetics, AnaConDa syringes, FlurAbsorb charcoal filters for removing halogenated hydrocarbon anaesthetic gases, different lines and connectors which can be used to connect the FlurAbsorb filter, adaptors, among others. The Companyâs main shareholders are board members, Linc AB and Magiola Consulting AB.

Sector

Medical Equipment, Supplies & Distribution

Calendar

23/07/2024 - Q2 2024 Earnings Release

More about the company